Hansoh Pharmaceutical Group (HKG:3692) has obtained drug registration approval for Hengmeida (Ibrexafungerp tablets) from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.
The approval is for use of the drug to treat vulvovaginal candidiasis in adult and post menarche adolescent women.